Key Points
- Insider sale: VP David Foehr sold 5,265 shares on Dec. 3 at an average $16.83 for $88,609.95, leaving him with 19,384 shares — a 21.36% reduction in his stake (SEC filing).
- Financials: CeriBell reported Q results that beat estimates (EPS ($0.37) vs. ($0.43) expected; revenue $22.59M vs. $21.78M) but remains unprofitable with a negative net margin of 63.35% and negative ROE.
- Market sentiment: Several large investors have increased positions while analysts show a consensus rating of "Moderate Buy" with a $25.17 price target amid some downward price-target revisions.
CeriBell, Inc. (NASDAQ:CBLL - Get Free Report) VP David Foehr sold 5,265 shares of the stock in a transaction that occurred on Wednesday, December 3rd. The stock was sold at an average price of $16.83, for a total value of $88,609.95. Following the completion of the transaction, the vice president owned 19,384 shares in the company, valued at $326,232.72. This represents a 21.36% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
CeriBell Stock Performance
CBLL stock opened at $19.72 on Friday. The firm has a 50 day moving average of $13.44 and a two-hundred day moving average of $14.41. CeriBell, Inc. has a 12 month low of $10.01 and a 12 month high of $32.75. The company has a market capitalization of $731.53 million, a price-to-earnings ratio of -13.06 and a beta of 1.35. The company has a quick ratio of 12.25, a current ratio of 12.65 and a debt-to-equity ratio of 0.12.
CeriBell (NASDAQ:CBLL - Get Free Report) last released its quarterly earnings results on Tuesday, November 4th. The company reported ($0.37) earnings per share for the quarter, beating analysts' consensus estimates of ($0.43) by $0.06. The business had revenue of $22.59 million for the quarter, compared to the consensus estimate of $21.78 million. CeriBell had a negative net margin of 63.35% and a negative return on equity of 29.63%. As a group, equities analysts anticipate that CeriBell, Inc. will post -2.46 EPS for the current fiscal year.
Hedge Funds Weigh In On CeriBell
Several large investors have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in shares of CeriBell by 11.1% during the 3rd quarter. Vanguard Group Inc. now owns 1,473,856 shares of the company's stock worth $16,935,000 after purchasing an additional 147,013 shares during the period. Yu Fan grew its position in CeriBell by 10.7% during the second quarter. Yu Fan now owns 1,353,166 shares of the company's stock worth $25,345,000 after buying an additional 130,964 shares in the last quarter. Novo Holdings A S increased its stake in CeriBell by 2.3% during the second quarter. Novo Holdings A S now owns 900,000 shares of the company's stock valued at $16,857,000 after acquiring an additional 20,000 shares during the period. TimesSquare Capital Management LLC increased its stake in CeriBell by 2.6% during the third quarter. TimesSquare Capital Management LLC now owns 817,645 shares of the company's stock valued at $9,395,000 after acquiring an additional 20,700 shares during the period. Finally, Millennium Management LLC raised its holdings in CeriBell by 41.8% in the 3rd quarter. Millennium Management LLC now owns 666,448 shares of the company's stock valued at $7,657,000 after acquiring an additional 196,299 shares in the last quarter.
Analyst Ratings Changes
A number of analysts have weighed in on CBLL shares. JPMorgan Chase & Co. reduced their price target on CeriBell from $21.00 to $17.00 and set an "overweight" rating for the company in a research report on Wednesday, November 5th. Raymond James Financial began coverage on CeriBell in a research note on Tuesday, October 21st. They issued a "strong-buy" rating and a $19.00 price objective on the stock. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of CeriBell in a research report on Wednesday, October 8th. Finally, TD Cowen dropped their price target on shares of CeriBell from $36.00 to $20.00 and set a "buy" rating on the stock in a research report on Wednesday, November 5th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $25.17.
Check Out Our Latest Stock Report on CBLL
CeriBell Company Profile
(
Get Free Report)
We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
